Insurance and Biosimilars: Will Your Claim Be Affected?

Yes, on the same footing as the originator. A biosimilar approved by CDSCO is an ordinary prescription medicine. No standard Indian policy excludes biosimilars as a category. What decides the payout is your sum insured and any sub-limit on the immunotherapy line — not the brand printed on the vial.

IRDAI's 2019 standardisation of exclusions requires Indian health policies to cover a defined list of modern treatment methods. Immunotherapy given as a monoclonal antibody injection is on that list. Cover for that list is frequently capped at a stated share of the sum insured, and the figure differs policy to policy. That cap, not the brand, is usually what a family runs into.

Different payers reach the same medicine by different routes, and each route has its own trap. The table below sets out how each one treats an approved biosimilar as of August 2026.

Not by naming one, and no IRDAI rule forces a brand. The pressure is indirect. A sub-limit, a reasonable-and-customary charges clause, or a query from the third-party administrator can leave the originator's extra cost unpaid. Practice varies between insurers, and most families meet it at pre-authorisation.

This is the part that surprises people. The policy document you read at purchase says nothing about biosimilars, so the question feels settled. It is not settled; it is simply deferred to the desk that approves your first cycle. Five mechanisms do the work.

There is a real limit to what an insurer can do, and it is worth knowing. India operates no separate interchangeability designation of the kind the United States applies, so an approved biosimilar is not automatically substituted at the pharmacy counter. Which brand you receive remains a prescriber decision, recorded cycle by cycle. An insurer can decline to fund a difference. It cannot change your prescription.

No comparison of quality between named manufacturers is made or implied anywhere on this page. Every product referred to here has been approved under the same Indian regulatory standard. Whether an approved biosimilar of your molecule is clinically appropriate for you is a question for your oncologist, and Is a Nivolumab Biosimilar as Good as Opdyta? sets out how that comparison is actually assessed.

You can be prescribed it, and no insurer can overrule your oncologist. What can happen is that the insurer funds only what it would have paid for the approved lower-cost version, and you cover the difference. Settle that figure in writing before the first cycle, never after the third.

The difference is not a rounding error on a long course, so the sequence below matters more than any single conversation. It takes a few days and it is the whole of the protection available to you.

1. Have the prescription written in full. Molecule, brand, dose, interval and the planned number of cycles, on the prescription itself rather than in a verbal plan.
2. Send it as a pre-authorisation, not a question. A pre-authorisation produces a written approved amount. A phone enquiry produces nothing you can rely on later.
3. Ask the brand question explicitly. Whether the approved amount changes if an approved biosimilar of the same molecule exists, and by how much per cycle.
4. Ask the billing desk for an itemised quote. The drug line separately from day-care admission, nursing, premedication, pre-cycle blood tests and consultation, so the brand difference is visible on its own.
5. Have any proposed brand change documented. If a switch is suggested part-way through, the reason and your consent belong in the case notes.
6. Keep every invoice and batch record. Reimbursement and product authenticity both depend on the same paperwork.

If the arithmetic ends up deciding how many cycles are affordable, that is a conversation to have with your oncologist rather than with the insurer. Stopping a working treatment early because the funding ran out at cycle six is a worse outcome than planning for a fully funded course from the start.

This page is not a policy interpretation, an insurance quote, or a price list, and it cannot tell you what your own insurer will approve. Only your policy schedule, your scheme's package list and a written pre-authorisation are binding on a claim. If your policy wording and this page disagree, your policy wording is right.

The medicines themselves are not for most patients, and no amount of cover changes that. Immune checkpoint inhibitors — biosimilar or originator — are appropriate for a minority of Indian cancer patients, and eligibility is decided on cancer type, stage, prior treatment and biomarker results long before cost enters the discussion. A medicine that is not approved for your diagnosis is not an option, at any price and under any policy.

They are also frequently unsuitable, or need considerable caution, for people with active autoimmune disease, people on long-term immunosuppression, organ-transplant recipients and patients whose performance status will not tolerate an immune-related reaction. That assessment belongs to your treating oncologist and cannot be made from a page.

Asking whether an approved biosimilar exists for a medicine you have already been prescribed is a different and entirely reasonable question. That is a conversation about brand within the same molecule, and your treating team can answer it directly.

Because the same capped benefit stretches several times further. A sub-limit is a fixed number of rupees. If an approved version of the same molecule is sold at a fraction of the reference price, that fixed number funds many more cycles. Nothing about the cap changes; only what it buys.

Until 2026 this argument had nothing to stand on in the checkpoint-inhibitor class, because there was no cheaper approved alternative to point at. That changed. Nivolumab's Indian patent lapsed in May 2026, and a domestically manufactured biosimilar launched in January 2026 at roughly a quarter of the reference price, according to published launch announcements and reported Indian pricing coverage. Those figures are indicative and dated to August 2026, and they are not a CION price for any named product. Tishtha: India's Nivolumab Biosimilar and What It Costs covers that launch in detail.

The same logic cuts the other way where no biosimilar exists. Pembrolizumab has no approved Indian biosimilar as of August 2026, and its Indian patent protection is expected to begin lapsing around 2028-29. For that molecule an insurer has no lower-cost comparator to hold up, so a reasonable-and-customary argument has nothing to compare against — though the sub-limit still applies in full. When Will a Pembrolizumab (Keytruda) Biosimilar Reach India? tracks where that stands.

Delaying treatment in the hope that a future biosimilar will lower the price is a clinical decision dressed as a financial one, and it rarely survives contact with an oncologist. What exists today is your policy schedule, your scheme's package list, an itemised quote and a written pre-authorisation.

Buying the vial outside the treating hospital's licensed pharmacy. Insurers reimburse against pharmacy invoices tied to the admission record. A privately sourced vial frequently has no admissible invoice at all, so a family that paid to save money ends up funding the whole line themselves.

The safety problem is larger than the claim, and it should not be softened. Counterfeit checkpoint inhibitors have been reported entering the Indian market around patent and pricing changes, and a very large price gap is precisely the environment in which a fake vial finds a buyer. A privately sourced vial carries no verifiable batch record and no cold-chain history, and cold chain is the part a diverted or repackaged product usually fails.

Two rules follow. These medicines should be dispensed and administered through the treating hospital's own licensed pharmacy, never through an intermediary or an online seller, however genuine the offer looks. And it is entirely reasonable to ask to see the vial, the batch number, the invoice and the cold-chain record before infusion. That is routine verification, not an accusation, and the same paperwork is what an insurer will want afterwards.

At CION centres, immunotherapy is administered as day care, and response-assessment PET-CT is coordinated at partner imaging centres and billed separately by them. Both points matter when you compare one hospital's quote with another's.

• Tishtha: India's Nivolumab Biosimilar and What It Costs — the January 2026 launch that gave insurers a lower-cost comparator in this drug class.
• Is a Nivolumab Biosimilar as Good as Opdyta? — how comparability is assessed, and what your oncologist is actually weighing.
• When Will a Pembrolizumab (Keytruda) Biosimilar Reach India? — why one molecule has an alternative and the other does not.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars and molecule comparisons.
• Immunotherapy at a glance — what this class of treatment does, who it suits, and who it does not.

Editorial information about insurance and scheme cover for a class of medicines — not an offer, a price list, a policy interpretation, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Insurance and scheme mechanics are described in general terms from IRDAI's published standardisation guidelines and the public rules of the named schemes; only your own policy schedule and a written pre-authorisation are binding. All pricing, patent and regulatory statements are indicative and dated to August 2026, drawn from published manufacturer launch announcements, regulatory filings and reported Indian pricing coverage. Whether any of these medicines applies to your treatment, and in which brand, is a decision for your treating oncologist.